Spravato has a boxed warning about this risk. A boxed warning is the most serious warning from the Food and Drug Administration (FDA). For details, see “Boxed warnings” in the introduction of ...

Cybin (CYBN) stock earns Guggenheim's Buy rating with a $35 target, as the firm cites blockbuster potential for CYB003 in line with J&J's (JNJ) Spravato. Read more here.

Johnson & Johnson (NYSE:JNJ) is currently addressing shareholder proposals regarding executive compensation and human rights ...

Johnson & Johnson (NYSE:JNJ) recently experienced a 12% price increase over the last quarter, largely driven by significant ...

Johnson & Johnson discontinues aticaprant's Phase 3 trial but explores future options. Another depression drug Spravato sales hit $1.01 billion ...

Elon Musk discussed his use of ketamine for depression during an interview, claiming it helps him combat negative mental ...

Up to 40% of people who suffer from depression are unable to find any relief for their condition. But now, Blessing ...

Ketamine advertisements are popping up all around us. With few regulations in place, might we be witnessing another opioid ...

Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly ...

SPRAVATO has been increasing in sales for the ... There's interest at the FDA as well, but it's a challenging one. Right? It's a very challenging indication, but has the potential to just really ...